

## Curriculum Vitae

### Jordan Brittini Milner (Watson)

1600 SW Archer Road  
HD-204  
Gainesville, FL 32610  
(386) 852-8933  
Jordan.milner@ufl.edu

### Education

UNDERGRADUATE  
2005-2009

B.S. University of South Florida, Tampa, Florida  
National Undergraduate Scholar Recipient, Graduate of Honors College  
“Comparing Mainland Puerto Ricans’ and Island Puerto Ricans’ Knowledge about Hereditary Cancer”, Gwendolyn Quinn, PhD

MEDICAL SCHOOL  
2009- 2014

MD St. George’s University School of Medicine, St. George, Grenada

RESIDENCY  
2014- 2017

Memorial University Medical Center/Mercer University School of Medicine, Savannah, Georgia  
Chief Resident  
“Characterizing Infant Mortality Risk Factors in Chatham County, Georgia”, Stephen Thacker, MD

FELLOWSHIP  
2017- 2020

Maria Fareri Children’s Hospital, Westchester Medical Center, New York Medical College  
Chief Fellow  
“Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing alpha/beta T cell and CD19+ B Cell Depletion: NYMC588” Mitchell S. Cairo, MD

### Licensure & Certification

#### LICENSURE

2022	Florida State Medical License (ME 15765)	Expiration Date: 01/31/2024
2020	Connecticut State Medical License (65444)	Expiration Date: 11/30/2022
2017	New York State Medical License (289664)	Expiration Date: 10/31/2022
2017	DEA Registration (FW6851845)	Expiration Date: 1/31/2023
2017	National Providers Identification (1558780197)	

#### CERTIFICATIONS

2017	American Board of Pediatrics	Renewal Date: October 2027
------	------------------------------	----------------------------

### Appointments & Employment

July 2022- Present	Assistant Professor of Pediatrics Division of Pediatric Hematology-Oncology and Stem Cell Transplantation Department of Pediatrics University of Florida
2020-June 2022	Assistant Professor of Pediatrics Division of Pediatric Hematology-Oncology and Stem Cell Transplantation Department of Pediatrics New York Medical College
2020- June 2022	Clinical Director of Hematotherapy Westchester Medical Center
2020 – June 2022	Clinical Director of Non-Malignant Transplantation
2020-DEC 2020	Assistant Professor of Research New York Medical College, Valhalla, NY
Other Employment 2018-2022	Per Diem Secondary Physician PM Pediatrics Urgent Care, Lake Success, NY

## Professional Organizations & Societies

### MEMBERSHIP

2014-2019	American Academy of Pediatrics
2017-present	American Society of Hematology
2018-present	American Society for Transplantation and Cellular Therapy
2019-present	American Society Pediatric Hematology Oncology
2019-present	American Society for Apheresis

## Service

### EXTRAMURAL SERVICES

#### Organizations & Societies

2017-2022	Volunteer Event Organizer Planning and organizing this head shaving event annually to benefit pediatric oncology research. St. Baldrick's Foundation
-----------	--

### INTRAMURAL SERVICE

#### Hospital

2018 to 2020	Member Assisted in feedback and quality changes amongst the Graduate Medical Education Committee. Graduate Medical Education Committee, Westchester Medical Center
--------------	--

## Teaching

### FORMAL TEACHING

2022	The Art of Manipulation: Advancements in Stem Cell Therapy University of Florida Pediatric Grand Rounds
2021	Transplantation for Non-Malignant Disorders Taught pediatric hematology, oncology fellows during their lecture series
2021	Introduction to Apheresis Procedures Taught pediatric hematology, oncology fellows during their lecture series
2021	Sinusoidal Obstructive Syndrome Taught pediatric hematology, oncology fellows during their lecture series
2020	New Techniques and Clinical Advances of Hematotherapy at Maria Fareri Children's Hospital Grand Rounds Series
2018-2021	Sickle Cell Disease Including Pain Management at Maria Fareri Children's Hospital Taught pediatric residents updated management of sickle cell patients in pain crisis. Maria Fareri Children's Hospital Residency Program
2018	Iron Deficiency in Teens: The Role of IV Iron Therapy Provided education to community pediatricians surrounding Maria Fareri Children's Hospital Current Topics in Hematology and Oncology for Primary Care Providers

## Research Program

### CLINICAL TRIALS

From	To	Title (Award #):	Your Role	Total Direct Costs
2018	2022	Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing alpha/beta T cell and CD19+ B Cell Depletion: NYMC588	Developed protocol, submitted to FDA, obtained IND	
		PI: Jordan Milner, MD	Sponsor of Trial	Source of Funding
From	To	Title (Award #)	Your Role	Total Direct Costs
2019	2022	NYMC-204 A Pilot Study to Determine the Safety of Defibrotide in Children with High Risk Kawasaki Disease	Assisted in development of protocol.	
			Sponsor of Trial	Source of Funding

		<b>PI: Mitchell S. Cairo, MD</b>		
--	--	----------------------------------	--	--

#### CLINICAL QUALITY

<b>From</b>	<b>To</b>	<b>Title of Project</b>	<b>Your Role</b>	<b>Results</b>
2020	2022	Assessment of Chronic Graft Versus Host Disease and Improvement in Charting	Analyze incidence of cGVHD and provide education for providers to improve coding	Ongoing at this time
2020	2021	Quality Assessment of Blood Transfusion and Apheresis Procedures in Adult and Pediatric Patients	Analyze rolling data	Less adverse events than national benchmarks
2017	2019	Bad Blood: Decreasing Central Line Lab Draw Errors	Analyzed data and assisted in QI planning	Decreased amount of lab draw errors over one year time

#### Scholarship

##### Peer-reviewed

##### PUBLICATIONS

##### Journal Articles

Thomas Gagliardi, **Jordan Milner**, Mitchell S. Cairo, Amir Steinberg. Concomitant Ruxolitinib and Ibrutinib for Graft-versus-Host Disease (GvHD): First Reported Use in Pediatric Patients. *Cureus* 14(9): e29195. Doi:10.7759/cureus.29195

Parsons SK, Rodday AM, Weidner RA, Morris E, Braniecki S, Shenoy S, Talano JA, Moore TB, Panarella A, Flower A, **Milner J**, Fabricatore S, Mahanti H, van de Ven C, Shi Q, Cairo MS. Significant improvement of child physical and emotional functioning after familial haploidentical stem cell transplant. *Bone Marrow Transplant.* 2022 Apr;57(4):586-592. doi: 10.1038/s41409-022-01584-y.

Friedman D, Dozor AJ, **Milner J**, D'Souza M, Talano JA, Moore TB, Shenoy S, Shi Q, Walters MC, Vichinsky E, Parsons SK, Braniecki S, Moorthy CR, Ayello J, Flower A, Morris E, Mahanti H, Fabricatore S, Klejmont L, van de Ven C, Baxter-Lowe LA, Cairo MS. Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation. *Bone Marrow Transplant.* 2021 Sep;56(9):2221-2230. doi: 10.1038/s41409-021-01298-7.

**Watson, JB**, Bidgoli, A, Johnston, JM. B-precursor Acute Lymphoblastic Leukemia Complicating 18q Deletion Syndrome. *Pediatric Blood Cancer*, 2018 Sep, 6; 65(12):e27436.

Gwendolyn Quinn, Susan Vadaparampil, Lindsey King, Cheryl Miree, Crystal Wilson, Opal Raj, **Jordan Watson**, Alana Lopez, Terrance L. Albrecht. Impact of physicians' discomfort and patient prognosis on discussion of fertility preservation with young cancer patients. *Patient Education and Counseling*, 2009 Dec, 77(3): 338-43.

Quinn GP, Vadaparampil ST, **Fertility Preservation Research Group**. Fertility Preservation and Adolescent/Young Adult Cancer Patients: Physician Communication Challenges. *J Adolesc Health*, 2009 Apr, 44(4): 394-400.

Quinn G, Vadaparampil S, Wilson C, King L, Choi J, Miree C, Friedman S, **Fertility Preservation Group**. (2007). High Risk Women's Attitudes toward Preimplantation Genetic Diagnosis. *Fertility and Sterility*, 2009 June, 91 (6): 2361-2368.

## PRESENTATIONS

### Local/Regional

- 2021 Incidence of Transplant Associated Thrombotic Microangiopathy: A Retrospective Review from 2015-2017.  
11<sup>th</sup> Annual Assistant Professor Pediatric Research Symposium, Valhalla, NY
- 2019 Bad Blood: Decreasing Central Line Lab Draw Errors  
Paul K. Woolf Research Day, Valhalla, NY
- 2018 “Long Term Pulmonary and Cardiac Effects of Myeloimmunoablative Conditioning Following Familial Allogeneic Stem Cell Transplant (AlloSCT) in High Risk Patients with Sickle Cell Disease.”  
Paul K. Woolf Research Day, Valhalla, NY
- 2017 “Pediatric Code Blue: Improving Performance and Outcomes using Mock Code” to faculty of both Memorial University Medical Center and Mercer University School of Medicine faculty.”  
Research Day, Memorial University Medical Center, Savannah, GA
- 2009 “Comparing Mainland Puerto Ricans’ and Island Puerto Ricans’ Knowledge about Hereditary Cancer”  
Undergraduate Research Symposium, University of South Florida, Tampa, FL

### National

- 2021 “Haploidentical Viral Specific Cytotoxic T-Lymphocytes (vCTLs) for the Treatment of Refractory Viral Infections in Primary Immunodeficiencies (PID) or Secondary Immunodeficiencies (SID) following Solid Organ Transplant or Allogeneic Stem Cell Transplantation in Children, Adolescent, Young Adult (CAYA) Patients  
Primary Immune Deficiency Treatment Consortium Tenth Annual Scientific Workshop, Pacific Grove, CA
- 2019 “Viral Cytotoxic T-Lymphocytes for Children, Adolescents, and Young Adults (CAYA) with refractory Viral Infections in Primary Immunodeficiencies (PID) or post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT)” Presented, Primary Immunodeficiencies Treatment Consortium Scientific Workshop, NY, NY
- 2017 “Characterizing Preventable Infant Mortality in Chatham County”  
Pediatric Academic Society, San Francisco, CA
- 2016 “Characterizing Infant Mortality Risk Factors in Chatham County, Georgia” to residents, medical students, attendings, and faculty of Memorial University Medical Center and Mercer University School of Medicine.”  
Research Day, Memorial University Medical Center, Savannah, GA

### International

- 2022 Safety and Efficacy of Dose Escalation of Defibrotide in Hematopoietic Stem Cell Transplantation (HSCT) Recipients with Sinusoidal Obstructive Syndrome (SOS) Refractory to Standard Treatment Doses of Defibrotide. Poster presentation presented by Rachel Friedmann. The American Society of Pediatric Hematology/Oncology Pediatric Transplantation and Cellular Therapy Consortium 2022 Joint Conference, #11. May 2022.
- 2022 Treating Children, Adolescents, and Young Adults (CAYA) with Refractory Viral Infections in Primary Immunodeficiencies (PID), or Post Solid Organ Transplant (SOT) or Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) with Virus Specific T-Lymphocytes (vCTLs). Oral presentation by Mitchell S. Cairo. The American Society of Pediatric Hematology/Oncology Pediatric Transplantation and Cellular Therapy Consortium 2022 Joint Conference, #19. May 2022.
- 2022 Feasibility, Safety, and Efficacy of Haploidentical, Viral Cytotoxic T-Lymphocytes for Children, Adolescents, and Young Adults (CAYA) with Refractory Viral Infections in Primary Immunodeficiencies (PID) Post Solid Organ Transplant (SOT) or Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT). Best Pediatric Abstracts Oral Session. Transplantation and Cellular Therapy meetings of the American Society of Transplantation and Cellular Therapy, #131, February 2022.
- 2022 Hematopoietic Cell Transplantation in 240 Patients with Chronic Granulomatous Disease: A PIDTC Report. Poster Presentation by Danielle E. Arnold. Transplantation and Cellular Therapy meetings of the American Society of Transplantation and Cellular Therapy, #125. February 2022.
- 2022 Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with High-Risk Sickle Cell Disease (SCD) or Beta Thalassemia Major Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812). Poster Presentation by Edo Schaefer. Transplantation and Cellular Therapy meetings of the American

- 2022 Society of Transplantation and Cellular Therapy, #438. February 2022.
- 2022 Safety and Efficacy of High Dose Granulocyte Colony Stimulating Factor Mobilization in Familial Haploidentical Adult Donors with Sickle Cell Trait Followed by CD34+ Cell Enrichment and Mononuclear Cell Add-Back Prior to Haploidentical Allogeneic Transplantation in High-Risk Sickle Cell Disease Recipients. Poster Presentation. Transplantation and Cellular Therapy meetings of the American Society of Transplantation and Cellular Therapy, #320. February 2022.
- 2022 The Safety, Feasibility, and Efficacy of Ganciclovir Prophylaxis through Day +100 in Pediatric Allogeneic Stem Cell Transplantation (AooSCT) Recipients: Bone Marrow Suppression Secondary to Ganciclovir May Limit Effectiveness. Poster Presentation by Liana Klejmont. Transplantation and Cellular Therapy meetings of the American Society of Transplantation and Cellular Therapy, #177. February 2022.
- 2022 Safety and Efficacy of Dose Escalation of Defibrotide in Hematopoietic Stem Cell Transplantation (HSCT) Recipients with Sinusoidal Obstructive Syndrome (SOS) Refractory to Standard Doses of Defibrotide. Poster Presentation presented by Rachel Friedmann. Transplantation and Cellular Therapy meetings of the American Society of Transplantation and Cellular Therapy, #182. February 2022.
- 2021 Manufacture and Immunological Characterization of GMP-Compliant Functional Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs® Cytokine Capture System. Accepted for oral presentation by Yaya Chu. 63<sup>rd</sup> American Society of Hematology Annual Meeting and Exposition, #476. Blood, November 2021.
- 2021 “The safety, feasibility, and efficacy of ganciclovir prophylaxis through day +100 in pediatric allogeneic stem cell transplantation recipients: Bone marrow suppression may limit effectiveness. Presented by Liana Klejmont, Transplantation and Cellular Therapy meetings of the American Society of Transplantation and Cellular Therapy meetings of the American Society of Transplantation and Cellular Therapy, #17158. Transplantation and Cellular Therapy, 27 (3, S):S172, #187.
- 2021 Safety and efficacy of dose escalation of defibrotide in hematopoietic stem cell transplantation recipients with sinusoidal obstructive syndrome refractory to standard doses of defibrotide. Presented by Rachel Friedmann, Transplantation and Cellular Therapy meetings of the American Society of Transplantation and Cellular Therapy meetings of the American Society of Transplantation and Cellular Therapy, #17171. Transplantation and Cellular Therapy, 27 (3, S):S174, #189.
- 2021 “Stable to improved long term cardiac pulmonary function in children, adolescents and young adults with high risk sickle cell disease following myeloimmunoablative conditioning and familial haploidentical stem cell transplantation. Presented, Transplantation and Cellular Therapy meetings of the American Society of Transplantation and Cellular Therapy meetings of the American Society of Transplantation and Cellular Therapy, #16972. Transplantation and Cellular Therapy, 27 (3, S):S316, #379.
- 2020 “Rapid Engraftment, Immune Cell Reconstitution and Sustained Donor Chimerism in Patients Receiving G-CSF Mobilized Peripheral Blood Stem Cells (PB-SC) from Related or Unrelated Donors Undergoing CD34 Enrichment with Mononuclear Cell (T cell) Addback in Children, Adolescents, and Adults with Malignant and Nonmalignant Diseases”. Presented, American Society of Hematology, #185. Blood, 136 (S1):32-33.
- 2020 “Preliminary Results of a Phase II Study to Determine the Safety of Defibrotide in Children and Adolescents with Sickle cell Disease-Associated Acute Chest Syndrome (IND 127812).” Presented, American Society of Hematology, #805. Blood, 136 (S1):8-9.
- 2020 “Preliminary safety results of defibrotide in SCD patients with acute chest syndrome (IND 127812). Presented, American Society of Pediatric Hematology/Oncology, #129. Pediatric Blood and Cancer, 67(S2):S44.
- 2020 “Neurocognitive outcomes in children, adolescents & young adults with high-risk sickle cell disease following familial haploidentical stem cell transplantation: A prospective study from pre-HSCT period to 2 years post HSCT (IND 14359). Presented by Susan Branietki Pediatric Transplantation & Cellular Therapy Consortium, #12. Pediatric Blood & Cancer, 67(S2):S223.
- 2020 “A Five Year Quality Assessment of Pediatric Apheresis Procedures and Blood Product Transfusions: 2014-2018”. Accepted, American Society of Apheresis Meeting.
- 2020 “Determining the Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease Following Myeloimmunoablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34+ Selection and T-Cell (CD3) Addback (IND127812)” Presented, Transplantation and Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and Center for

- International Blood and Marrow Transplant Research, #314. Biology of Blood and Marrow Transplantation, 26(3S):S212.
- 2019 “Preliminary Results in the treatment of refractory viral (CMV, ADV, BK, or EBV) infections with related donor viral cytotoxic T lymphocytes (vCTLs) for children, adolescents and young adults (CAYA) Recipients following allogeneic hematopoietic stem cell transplantation (AlloHSCT) IND17449). Presented by Janet Ayello, 2<sup>nd</sup> International Symposium on Biology, Prevention, and Treatment of Toxicities after Transplantation and Cellular Therapy, 2019.
- 2019 “Processing of G-CSF Mobilized Peripheral Blood Hematopoietic Progenitor Cells (PB-HPC) from Matched- related or Unrelated Donors Undergoing CD34 enrichment with T cell Addback in Children, Adolescents and Adults with Malignant and Nonmalignant Diseases: Rapid Engraftment, Immune Cell Reconstitution and Sustained Donor Chimerism” Presented, Transplantation and Cellular Therapy Meeting of Association of Blood and Marrow Transplantation, Houston, Texas, Biology of Blood and Marrow Transplantation, #250. Biology of Blood and Marrow Transplantation, S1, 25(3):S181.